Epithalon (Epitalon)

Epithalon (Epitalon, Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology as the minimal active sequence derived from Epithalamin — a bovine pineal gland extract with a history in Soviet and Russian longevity research dating to the 1970s. Epithalon represents the shortest peptide in Khavinson's bioregulator peptide programme — a research framework proposing that short tissue-derived peptides act as endogenous regulators of gene expression and can restore age-related transcriptional changes.

The biological rationale for pineal-derived research compounds centres on the progressive age-related decline in pineal gland function. Melatonin production by pinealocytes — driven by AANAT (arylalkylamine N-acetyltransferase) as the rate-limiting enzyme — declines approximately 50-80% between young adulthood and old age in published cross-sectional studies. This melatonin decline contributes to circadian rhythm disruption, reduced antioxidant and immunoregulatory melatonin signalling throughout the body, and downstream changes in cellular maintenance pathways. Epithalon has been studied as a potential restorer of pineal transcriptional activity in aged cells.

The most widely cited Epithalon research finding concerns telomerase activation. Khavinson et al. (Bulletin of Experimental Biology and Medicine, 2003) reported that Epithalon treatment of human somatic cells increased telomerase activity and extended replicative lifespan beyond normal Hayflick limit expectations — a finding that positions Epithalon at the intersection of telomere biology, replicative senescence, and ageing research. Telomerase (TERT/TERC complex) adds TTAGGG repeat sequences to chromosome ends, counteracting telomere shortening during cell division. In somatic cells, telomerase is normally repressed and telomeres shorten with each division until critically short telomeres trigger senescence or apoptosis. If Epithalon can partially restore telomerase activity, this would represent a potential mechanism for extending replicative capacity in aged cell populations.

Mechanistically, Epithalon has been proposed to act as an epigenetic regulator through chromatin remodelling effects. Published data from Khavinson's group using chromatin immunoprecipitation and reporter assay approaches has suggested that Epithalon increases promoter accessibility for specific genes — including AANAT and other pineal-specific transcription targets — consistent with a model where the tetrapeptide influences histone modification states or chromatin-associated protein interactions to restore gene expression patterns altered by ageing.

The circadian biology research context for Epithalon complements Melatonin receptor pharmacology research. While Melatonin research examines downstream MT1/MT2 receptor signalling, Epithalon research addresses upstream pineal regulation — potentially restoring the source of melatonin production rather than supplementing its downstream signalling. Used together, these two compounds provide complementary tools for studying different levels of the pineal-circadian axis: production upstream (Epithalon) and receptor pharmacology downstream (Melatonin).

Laboratory research applications include: telomerase activity assays (TRAP — Telomere Repeat Amplification Protocol) in human fibroblasts at passages approaching the Hayflick limit; AANAT mRNA and protein expression in pinealocyte or pineal-derived cell models; antioxidant assays (DPPH, ABTS radical scavenging, TBARS lipid peroxidation); circadian clock gene expression profiling (CLOCK, BMAL1, PER1/2, CRY1/2 by qRT-PCR) in aged cell models; and cell cycle analysis by flow cytometry in normally senescent cell populations following Epithalon treatment.

MW: 390.35 g/mol. CAS: 307297-39-8. Molecular formula: C14H22N4O9. Freely water-soluble. Reconstitute in bacteriostatic water at 1mg/mL. Store lyophilised at -20°C. For laboratory and analytical research purposes only.